P

Inventor

WU QILONG

CN31 patents
⚠️ This page may combine multiple inventors who share the name “WU QILONG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

NOVARTIS AG

21 patents
US10174095B2Jan 8, 2019

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

NOVARTIS AG41 citations96
US9777061B2Oct 3, 2017

Treatment of cancer using a CD33 chimeric antigen receptor

NOVARTIS AG85 citations96
US11084880B2Aug 10, 2021

Anti-BCMA chimeric antigen receptor

NOVARTIS AG15 citations93
US10287354B2May 14, 2019

Regulatable chimeric antigen receptor

NOVARTIS AG29 citations92
US10640569B2May 5, 2020

Human mesothelin chimeric antigen receptors and uses thereof

NOVARTIS AG15 citations83
US10654914B2May 19, 2020

Polyomavirus neutralizing antibodies

NOVARTIS AG5 citations82
US10577417B2Mar 3, 2020

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

NOVARTIS AG10 citations82
US10450366B2Oct 22, 2019

Polyomavirus neutralizing antibodies

NOVARTIS AG5 citations82
US10435460B2Oct 8, 2019

Polyomavirus neutralizing antibodies

NOVARTIS AG5 citations82
US11639378B2May 2, 2023

Polyomavirus neutralizing antibodies

NOVARTIS AG1 citations71
US11161894B2Nov 2, 2021

Polyomavirus neutralizing antibodies

NOVARTIS AG2 citations71
US10568947B2Feb 25, 2020

Treatment of cancer using a CLL-1 chimeric antigen receptor

NOVARTIS AG6 citations71
US11591404B2Feb 28, 2023

Treatment of cancer using a CD123 chimeric antigen receptor

NOVARTIS AG0 citations62
US10703819B2Jul 7, 2020

Treatment of cancer using a CD123 chimeric antigen receptor

NOVARTIS AG1 citations62
US12338287B2Jun 24, 2025

Treatment of cancer using a CD33 chimeric antigen receptor

NOVARTIS AG0 citations61
US12077571B2Sep 3, 2024

Polyomavirus neutralizing antibodies

NOVARTIS AG0 citations61
US11578130B2Feb 14, 2023

Regulatable chimeric antigen receptor

NOVARTIS AG1 citations61
US11459390B2Oct 4, 2022

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

NOVARTIS AG0 citations61
US10851166B2Dec 1, 2020

Treatment of cancer using a CD33 chimeric antigen receptor

NOVARTIS AG1 citations61
US11999794B2Jun 4, 2024

Human mesothelin chimeric antigen receptors and uses thereof

NOVARTIS AG0 citations60
US11981731B2May 14, 2024

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

NOVARTIS AG0 citations60

XIAMEN CHANGELIGHT CO LTD

4 patents

BROGDON JENNIFER

1 patent

ABEND JOHANNA

1 patent

SHENZHEN JIANYOUPINSHANG TECH CO LTD

1 patent

CHANGXIN MEMORY TECH INC

1 patent

UNIV PENNSYLVANIA

1 patent

WUHAN INST TECHNOLOGY

1 patent